Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 3,275.00
+40.00 (1.24%)
Sep 19, 2025, 3:30 PM KST
Xcell Therapeutics Revenue
Xcell Therapeutics had revenue of 221.28M KRW in the quarter ending June 30, 2025, a decrease of -53.74%. This brings the company's revenue in the last twelve months to 1.49B, down -16.77% year-over-year. In the year 2024, Xcell Therapeutics had annual revenue of 1.93B with 72.11% growth.
Revenue (ttm)
1.49B
Revenue Growth
-16.77%
P/S Ratio
24.12
Revenue / Employee
n/a
Employees
n/a
Market Cap
35.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.93B | 810.45M | 72.11% |
| Dec 31, 2023 | 1.12B | 103.86M | 10.18% |
| Dec 31, 2022 | 1.02B | -946.25M | -48.12% |
| Dec 31, 2021 | 1.97B | 1.43B | 264.00% |
| Dec 31, 2020 | 540.20M | 454.60M | 531.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| SK Biopharmaceuticals | 620.28B |
| Yuhan | 2,165.44B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |